XORTX Announces Termination and Postponement of Investor Relations Program

XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.